Compounds > 5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepin-7-ol
Page last updated: 2024-09-05

5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepin-7-ol and Dementia Praecox

5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepin-7-ol has been researched along with Dementia Praecox in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andersen, J; Andersen, M; Clemmesen, L; Fensbo, C; Gerlach, J; Hansen, L; Karle, J; Lublin, H; Skrumsager, BK; Sloth-Nielsen, M1

Trials

1 trial(s) available for 5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepin-7-ol and Dementia Praecox

ArticleYear
NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia.
    Psychopharmacology, 1995, Volume: 121, Issue:3

    Topics: Adult; Benzazepines; Benzofurans; Dopamine Antagonists; Follow-Up Studies; Humans; Male; Placebo Effect; Receptors, Dopamine D1; Schizophrenia; Treatment Outcome

1995